Stay updated on PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC
Sign up to get notified when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.

Latest updates to the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check37 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check51 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check58 days agoChange DetectedThe website has updated the intervention details to include a verified status by Jiangsu HengRui Medicine Co., Ltd. and has upgraded to revision v2.14.0, while the previous type of intervention and revision v2.13.3 have been removed.SummaryDifference3%
- Check88 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
Stay in the know with updates to PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC
Enter your email address, and we'll notify you when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.